Bridge clinical data gaps and maintain CE marking with scientifically robust, end-to-end Post-Market Clinical Follow-up survey solutions designed for Notified Body approval.
250+
PMCF Surveys Completed
100%
NB Acceptance Rate
100K+
Global HCP Network
28
EU Countries Covered
01 / 07
What is Post-Market Clinical Follow-up?
Post-Market Clinical Follow-up (PMCF) is a critical component of a manufacturer's post-market surveillance obligations under EU MDR (2017/745) and IVDR (2017/746). PMCF activities are designed to proactively collect and evaluate clinical data on a CE-marked device to confirm ongoing safety, performance, and clinical benefit throughout its lifecycle. We support medical device and diagnostics manufacturers in designing, executing, and reporting PMCF surveys that are scientifically robust, regulator-ready, and aligned with notified body expectations. Important: for many devices (especially legacy devices), pre-market clinical evidence alone is no longer sufficient — notified bodies increasingly expect active PMCF data generation, not just literature updates.
Why PMCF Is Required Under MDR/IVDR
Under MDR/IVDR, manufacturers must demonstrate that:
The device continues to perform as intended in real-world clinical use
Identified and residual risks remain acceptable
No new safety signals or performance gaps emerge post-commercialization
Clinical evidence remains current, relevant, and sufficient
02 / 07
Why Level 4 Evidence Matters for Your CER
Per MDCG 2020-6, Notified Bodies evaluate clinical evidence based on a defined hierarchy. Generic user feedback (Level 8) is no longer sufficient. Our PMCF surveys are specifically designed to generate Level 4 patient-specific clinical data that directly addresses residual risks and state-of-the-art comparisons.
01
Scientifically Validated Endpoints
Questionnaires designed with clinical validity and reliability testing
02
Statistical Rigor
Sample size justification and pre-specified analysis plans
03
Direct Risk Addressal
Survey endpoints mapped to specific residual risks from your RMF
MDCG 2020-6 Evidence Hierarchy
Level 1–2
High-Quality Clinical Studies : RCTs, meta-analyses of RCTs
Case Series & Reports : Uncontrolled observational data
* Supplementary evidence only
Level 7–8
General User Feedback : Non-structured opinions, general questionnaires
* Insufficient for regulatory purposes
03 / 07
Common Challenges
Many medical device companies find PMCF activities challenging due to resource constraints, unclear requirements, and lack of specialized expertise.
Unclear NB Expectations
Notified bodies have varying and evolving expectations for PMCF activities, making it difficult to know what level of evidence will satisfy reviewers.
Poorly Defined Objectives
PMCF objectives that fail to close clinical evidence gaps result in wasted resources and data that doesn't address the real regulatory questions.
Low Physician Participation
Engaging busy healthcare professionals to participate in surveys is challenging without established relationships and proper incentive structures.
Non-Defensible Surveys
Surveys that are not clinically meaningful or methodologically sound cannot withstand NB scrutiny and may be rejected entirely.
Translation to Reports
Difficulty translating survey outputs into usable PMCF Evaluation Reports and CER updates that meet MDCG template requirements.
04 / 07
Our PMCF Services
We bridge regulatory requirements with real-world clinical practice, ensuring PMCF data is both collectable and compliant — transforming PMCF from a compliance burden into a strategic asset for your clinical evidence portfolio. We offer end-to-end as well as modular service offerings across the PMCF/PMPF survey — you can choose all or any of the below offerings to suit your specific requirements.
01
PMCF/PMPF User Survey Plan
MDCG compliant PMCF/PMPF User Survey Plan creation along with SAS plan and sample size determination for PMCF/PMPF user survey data collection.
Gap analysis & scope definition
Endpoint specification aligned to residual risks
Sample size justification (SAS plan)
Ethical & regulatory pathway mapping
Statistical analysis plan
Key deliverable
MDCG 2020-7 compliant PMCF Plan ready for NB review
02
Survey Questionnaire
We design highly robust survey questionnaires that capture critical post-market data through scientifically sound methodologies in professional grade survey platforms.
RWE generated using online surveys programmed in professional grade market research survey platforms among authenticated empanelled healthcare professionals.
100K+ global HCP network access
EMR/patient case form data capture
Real-time data quality monitoring
CFR Part 11 compliant EDC
Retrospective record-based collection
Key deliverable
Clean, validated dataset with full audit trail
04
PMCF/PMPF User Survey Report
MDCG compliant PMCF/PMPF User Survey Report creation using the Excel/SPSS raw data and Excel Data Tables generated from the online surveys.
Full statistical analysis & interpretation
Safety & performance conclusions
State-of-the-art comparison
CER integration narrative
NB response support
Key deliverable
MDCG 2020-8 compliant PMCF Evaluation Report
05 / 07
A Proven, End-to-End PMCF Survey Process
Our 7-step methodology ensures every PMCF survey is scientifically rigorous, regulatory-defensible, and designed for notified body acceptance from day one.
01
MDCG-Aligned Study Design
Every PMCF/PMPF engagement begins with a clearly defined user survey plan aligned to MDCG 2020-7 requirements.
Study objectives and rationale
Target study population and geographies
Sample size calculation with documented justification
Primary and secondary endpoints (performance, safety, off-label use)
Reports formatted per MDCG 2020-8 template, designed for seamless CER integration and NB submission.
Therapeutic Expertise
Specialized experience in orthopedics, cardiovascular, IVD, dental, and Class III implantables.
FAQ
Frequently asked questions
Practical answers on scope, methodology, and compliance for PMCF / PMPF Surveys.
01When is a PMCF survey sufficient versus a clinical investigation?
PMCF surveys are appropriate when your device has substantial pre-market clinical data and you need to confirm long-term safety and performance, monitor residual risks, or gather real-world evidence. Full clinical investigations are typically required for novel devices, Class III implantables with limited clinical history, or when a survey cannot adequately address identified clinical gaps. Our gap assessment recommends the most appropriate approach for your situation.
02How do you calculate sample size for PMCF surveys?
Sample size is determined from the primary endpoints, expected effect sizes, and the statistical power required to detect clinically meaningful differences. We use established methods for proportions (safety and performance rates) or means (continuous outcomes), and exact binomial methods for rare adverse events. All calculations are documented with justification in the protocol and reviewed by our biostatistics team.
03Is ethical approval required for PMCF surveys?
It varies by country and survey design. Surveys involving only healthcare professionals about their clinical experience may not require ethics approval, whereas surveys collecting patient-reported outcomes, accessing patient records, or involving direct patient participation typically require ethics-committee review. We assess the requirements for each target country and manage the submission process.
04What distinguishes Level 4 from Level 8 evidence?
Level 4 evidence (per MDCG 2020-6) consists of structured surveys collecting patient-specific clinical outcomes, safety data, and performance metrics with proper methodology. Level 8 evidence is general user feedback or opinion without structured methodology — increasingly rejected by Notified Bodies as insufficient. Our surveys are designed specifically to generate Level 4 evidence that addresses your device's residual risks.
05How long does a typical PMCF survey take?
Timelines depend on scope, sample size, and geographic reach. A focused single-country HCP survey typically takes 3–4 months from protocol finalization to final report; multi-country patient-outcome surveys may require 6–9 months. Our established HCP network enables faster recruitment than building site relationships from scratch — often reducing timelines by up to 40%.
Yes — this is one of the most common use cases. Many devices certified under MDD have limited clinical data that doesn't meet MDR Article 61 requirements. PMCF surveys can efficiently generate real-world evidence on safety, performance, and clinical benefit to bridge these gaps, often more cost-effectively than retrospective clinical studies. We design surveys that directly address the gaps identified in your Clinical Evaluation Report.
07What data-management systems do you use?
We use CFR Part 11 and ISO 14155 compliant Electronic Data Capture (EDC) systems with audit trails, electronic signatures, and data-integrity controls. Real-time data-quality monitoring enables early issue identification, and all systems meet the standards Notified Bodies expect for clinical data capture.
08How do you ensure survey responses are genuine and reliable?
We implement multiple validation mechanisms: HCP verification against professional registries, response-consistency checks, statistical outlier detection, and response-time analysis. For patient surveys, we use verified recruitment pathways through treating physicians. All methodologies are documented in the protocol for regulatory transparency.
A global dental device manufacturer engaged us to run a post-market clinical follow-up survey among dentists in the US and EU5, capturing clinician-reported evidence on the performance, safety, and usability of its endodontic paper points.
A global dental manufacturer engaged us to run a post-market clinical follow-up survey among dentists in the US and China, capturing clinician-reported evidence on the safety, performance, and esthetics of its sonic-activated bulk-fill composite.
A global dental device manufacturer engaged us to run a post-market clinical follow-up survey among general practice dentists in the US, Spain, and Romania, capturing clinician-reported evidence on the performance, safety, and esthetics of its temporary crown and bridge material.